bioTheranostics reports data for molecular cancer classification assay

bioTheranostics Inc. reported data from a study showing that site-specific chemotherapy as directed by the CancerTYPE ID test significantly improved median overall survival (OS) vs. empiric therapy (12.5 vs. 4.7 months) in a subset of 194 evaluable previously untreated patients with carcinoma of unknown primary origin. CancerTYPE ID also predicted a site of tumor origin in 98% of 252 patients with carcinoma of unknown primary origin that were enrolled in the trial and had successful assays performed. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...